CJC-1295 + Ipamorelin: The Complete Research Protocol

Growth hormone release is controlled by two inputs that work on different parts of the system. GHRH, produced in the hypothalamus, binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. That signal governs how much hormone the cell is able to make and hold in a releasable pool. Ghrelin, and the synthetic ghrelin mimetics, bind the growth hormone secretagogue receptor (GHS-R1a) on the same cells and act as the release trigger, partly by suppressing somatostatin tone.

Put simply: GHRH sets the amplitude ceiling, the ghrelin mimetic pulls the trigger. Each compound is more effective when the other is present, and that is measured pharmacology rather than a marketing claim.

The clearest human dataset comes from a 1995 study in J Clin Endocrinol Metab that tested GHRH alone, the ghrelin mimetic GHRP-6 alone, and both together in eleven healthy controls. Mean GH area under the curve was 483.7 after GHRH, 1434.8 after GHRP-6, and 3771.5 after the combination. The combined response was significantly greater than the arithmetic sum of the two single responses, which is the definition of synergy, and GHRP-6 was on its own roughly three times more potent than GHRH.

The same study produced the detail that matters most for protocol design. In patients with hypothalamopituitary disconnection, the GHRP-6 response collapsed to 97.3 while the GHRH response stayed intact. The ghrelin mimetic therefore depends on an intact hypothalamus. Its trigger action is not purely a pituitary event, which is why the two compounds remain complementary rather than redundant.

CJC-1295 exists in two forms and they are not interchangeable. The original molecule, identified in a 2005 paper in Endocrinology, is a tetrasubstituted form of human GRF(1-29) with a maleimidopropionamide linker on a C-terminal lysine. That linker binds covalently to cysteine 34 of circulating serum albumin, so the peptide rides along with albumin and stays in circulation. In rats it produced a fourfold increase in GH area under the curve compared with plain GRF(1-29) and was still detectable in plasma beyond 72 hours. The substitution pattern also makes it resistant to DPP-IV cleavage, which is the enzyme that destroys native GHRH within minutes.

The human pharmacokinetics of the DAC form were published in 2006 in J Clin Endocrinol Metab. After a single subcutaneous injection, mean plasma GH rose two- to tenfold for six days or more and IGF-1 rose 1.5 to threefold for nine to eleven days, with an estimated half-life between 5.8 and 8.1 days. Repeated dosing kept IGF-1 above baseline for up to 28 days, and the authors reported no serious adverse reactions and better tolerability at 30 and 60 micrograms per kilogram than at higher doses.

A follow-up study in the same journal tested what continuous GHRH exposure does to the pulse pattern. Healthy men aged 20 to 40 received a single injection of 60 or 90 micrograms per kilogram; overnight sampling every twenty minutes showed trough GH up 7.5-fold, mean GH up 46 percent and IGF-1 up 45 percent, with pulse frequency and magnitude unchanged. The research community has repeated for years that the DAC form causes a continuous GH bleed that flattens pulsatility. In the only human dataset available for that compound, pulsatility was preserved and it was the baseline between pulses that moved.

The non-DAC variant keeps the same four stabilizing substitutions but drops the albumin-binding linker. Its plasma residence time is therefore measured in minutes rather than days, and the figure usually quoted in research literature, roughly 30 minutes, comes from its stability profile rather than from a dedicated human pharmacokinetic study. We are flagging that distinction deliberately, because a number repeated without its source is the same failure mode this site criticises in COAs.

Practical consequence: the two variants answer different research questions, and protocols written for one are not valid for the other. A vendor listing that does not state which form is being sold cannot be evaluated at all.

Ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was characterized in a 1998 paper in European Journal of Endocrinology, which reported an EC50 of 1.3 plus or minus 0.4 nanomoles per litre in primary rat pituitary cells, comparable to GHRP-6 at 2.2 nanomoles per litre, and an ED50 of 2.3 nanomoles per kilogram in conscious swine.

The reason ipamorelin replaced GHRP-6 in most modern stacks is the side-effect profile in that same work. GHRP-6 and GHRP-2 both raised plasma ACTH and cortisol. Ipamorelin did not, and that held true at doses more than 200 times the ED50 for GH release. None of the test compounds affected FSH, LH, prolactin or TSH. That is a genuinely unusual selectivity window and it is the strongest argument for this peptide over the older GHRPs.

The human pharmacokinetics were modelled in a 1999 study in Pharmaceutical Research, using fifteen-minute infusions in healthy male volunteers across five dose levels from 4.21 to 140.45 nanomoles per kilogram. Disposition was dose-proportional, with a terminal half-life of about two hours, clearance of 0.078 litres per hour per kilogram and a steady-state volume of distribution of 0.22 litres per kilogram. GH rose in a single episode peaking at 0.67 hours, with a half-maximal concentration of 214 nanomoles per litre.

Two findings from that study deserve more attention than they get. Inter-individual variability in the pharmacodynamic response was larger than in the pharmacokinetic parameters, which means the same dose does not produce the same GH response across subjects. And the GH response was a single pulse followed by exponential decline, which is the pharmacological argument for spacing doses rather than stacking them.

One caveat is routinely omitted: ghrelin receptor agonism is not silent outside the pituitary. A 2009 study in Journal of Pharmacology and Experimental Therapeutics using a rodent model of postoperative ileus found that a single 1 milligram per kilogram dose shortened the time to first bowel movement, while repeated dosing four times daily for two days increased faecal pellet output, food intake and body-weight gain. The claim that ipamorelin has no appetite or gut effect is therefore a statement about single-dose selectivity in swine, not a blanket property of the molecule.

Concentrations in practice. A 2 mg CJC-1295 vial reconstituted with 2.0 ml of bacteriostatic water gives 1 mg per ml, which is 100 micrograms per 0.1 ml or 10 units on a U-100 insulin syringe; the same 2.0 ml on a 5 mg vial gives 2.5 mg per ml. Ipamorelin at 2 mg with 2.0 ml gives the same 100 micrograms per 0.1 ml, and a 5 mg vial with 2.5 ml gives 200 micrograms per 0.1 ml. Convert any of these combinations with the reconstitution calculator rather than doing the arithmetic under time pressure.

On the 1:1 ratio. Matching milligrams of the two peptides is a convention, not a pharmacological requirement. The defensible version of the pairing argument is that the compounds act at different nodes of the same axis, so both should be present in the same window. The exact ratio is a design variable that depends on the research question.

Timing and the pulsatility argument. This is where the animal literature is genuinely instructive. A 2001 study in Journal of Neuroendocrinology compared continuous infusion of GHRP-6 with pulsatile infusion given every three hours in growth-retarded rats. Continuous exposure produced only transient weight gain and desensitisation to later bolus challenge, accompanied by elevated periventricular somatostatin mRNA. Pulsatile dosing produced sustained growth and sustained GH responses. A 2003 study in Endocrinology reproduced the pattern with ghrelin and GHRP-6: every-three-hour intermittent infusion accelerated skeletal growth, while continuous infusion suppressed the amplitude of spontaneous GH secretory episodes.

The translation to protocol design is straightforward. The axis responds to pulses, and a plateau is read by the system as a signal to downregulate. Where those administration windows are placed relative to sleep and fasting is a research-design decision. What the data argues against is deliberately engineering continuous exposure with a short-acting ghrelin mimetic.

Storage and handling. Store both peptides lyophilized at minus 20 degrees Celsius, protected from light and moisture. After reconstitution they belong at 2 to 8 degrees Celsius and should be used within 21 days according to the compound profiles, and reconstituted solution should never be frozen and thawed repeatedly. Bacteriostatic water is the correct diluent for a multi-dose vial; sterile water for injection is a single-use option only.

• No trial of this combination exists. The synergy evidence comes from acute single-dose testing of GHRH plus GHRP-6 in humans. GHRP-6 is not ipamorelin, and an acute stimulation test is not a multi-week protocol. The mechanistic case for pairing is strong; the protocol-level evidence is absent.
• The human safety data is short and narrow. The CJC-1295 dataset covers 28-day and 49-day trials at specific ascending doses. Nobody has published a long-term safety study of the non-DAC variant in humans at all.
• IGF-1 is a poor proxy for exposure. The pulse-pattern study found that changes in IGF-1 did not correlate with any measured GH secretion parameter. A single IGF-1 reading cannot tell you what a protocol is doing.
• Response variability is large and poorly explained. Between-subject variability in GH response exceeded pharmacokinetic variability, and the axis behaves differently with age. Dose extrapolation from one person to the next is unsupported.
• Neither compound is an approved drug. Tesamorelin is the only GHRH analog with regulatory approval, granted for HIV-associated lipodystrophy. CJC-1295 and ipamorelin are research materials, and a vendor selling unverified vials is the biggest uncontrolled variable in any protocol.

Verification still comes first. A protocol built on a vial that is not what the label claims is not a protocol, it is noise with a syringe attached. Every batch should carry an independent third-party HPLC certificate above 99 percent with mass spectrometry confirmation; the COA red flags report shows how to tell a laboratory document from a marketing PDF.